Mark Merritt is President and CEO of the Pharmaceutical Care Management Association (PCMA), the national association representing America’s pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.

Mr. Merritt took the helm of PCMA in March 2003 and quickly raised the industry’s profile. He is repeatedly ranked as one of the most effective trade association CEOs in America and has been inducted into the U.S. Chamber of Commerce’s elite “Association Committee of 100,” representing America’s top trade association executives. In recognition of his aggressive advocacy for lower cost prescription medications, the Generic Pharmaceutical Association (GPhA), which represents the world’s leading generic drug manufacturers, honored Mr. Merritt with its prestigious “Outstanding Contribution” award. Mr. Merritt serves on the Editorial Advisory Board for Drug Benefit News and on the Board of Directors for the Public Affairs Council, the leading association for public affairs professionals worldwide.

Mr. Merritt is credited with designing and implementing innovative, campaign-style strategies that go beyond traditional Washington-style lobbying campaigns. Mr. Merritt has pioneered strategies that reach beyond the boundaries of Washington politics to communicate more effectively with diverse constituencies from Wall Street to Main Street to Hollywood.

Prior to PCMA, Mr. Merritt served as a senior strategist with America’s Health Insurance Plans and the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as with the presidential campaigns of current U.S. Senator Lamar Alexander and former Senator Robert Dole. Mr. Merritt has also served as a Fellow at Harvard University’s John F. Kennedy School of Government, where he lectured on the intersection between public policy and the news media.

He holds both an MA and BA from Georgetown University.